Sentiment Trading

ADMA Biologics reports strong Q1 performance, with a 42.17% increase in sales and a significant improvement in earnings, positioning the company for continued growth in the IVIG market.

ADMA Biologics Inc. reported strong Q1 financial performance, with a 42.17% revenue increase and projected EPS of $0.153, positioning the company for continued success in the growing IVIG market.

ADMA Biologics Inc.’s stock reached an all-time high of $24.02 after the FDA approved a new production process, boosting investor confidence and the company’s market position.

ADMA Biologics Inc. reached an all-time high of $24.02 on April 28, 2025, driven by FDA approval for a production yield enhancement process and investor confidence in its growth potential.